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Three major theories of cancer-somatic mutation, virus causation, and faulty differen-
tiation-are proposed to involve alterations in DNA structure. Each results finally in terms
of failures in the normal intercellular communication that involves feedback between dif-
ferentiated cells acting on less differentiated cells still capable of proliferation. The historical
background of the latter idea is traced to Osgood, to Weiss and Kavanau, and to Iversen. The
historical background of concepts of initiation and promotion are traced to Berenblum and
Mottram and the Boutwell concept of promotion as gene activation is cited. It is proposed that
gene activation by promoters is a valid concept and that it results from the blocking of the
normal intercellular communication postulated by Osgood and others. The problem of
explaining the low probability of cancer following initiators or promoters acting alone is cited
as a problem in basic science. A hypothesis to solve the problem is proposed: Cancer results
from two or more relevant mutations; promoters enhance proliferation of cells with one
relevant mutation, thereby increasing the probability of obtaining a cell with two relevant
mutations. A new scheme of five stages of hepatocarcinogenesis is proposed in terms of the
hypothesis and available data.
INTRODUCTION
Twenty-six years ago I had the honor to present the Seventh Edgar Allen
Memorial Lecture at this University and I am privileged today to be here again to
help celebrate another milestone in the history of Yale University and its contribu-
tions to cancer research.
On that earlier occasion I had the temerity to speak on "Ten years of Cancer
Research." In a similar vein, today I would have to admit to "Forty years of Cancer
Research," but I no longer feel justified in trying to recount all the adventures and
misadventures covered in that time span. Instead I have chosen to focus on
"Initiation and Promotion in Cancer Formation," which might be subtitled "The
Importance of Studies on Intercellular Communication," because, in the framework
of this symposium, this is where I think much attention should be focused in "The
Decade Ahead."
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For some years I have believed that the three major theories on the nature of
cancer could be integrated into a single conceptual framework. According to these
theories, which have been considered as mutually exclusive, cancer is caused by
somatic mutations, by viruses, or by faulty differentiation. At the center is the
somatic mutation theory, formerly incompatible with the virus theory and bitterly
opposed by Peyton Rous [1]. Today the virus theory is no longer incompatible with
the somatic mutation theory because it is comprehended in terms of altered DNA
structures, following the brilliant intuition by Howard Temin and the subsequent
experiments by Temin and by Baltimore [1].
The third remaining theory is that cancer is merely a case offaulty differentiation,
but it is always implied that this is without altered DNA structures, i.e., without
somatic mutation [2]. I disagree with this view. I believe that cancer is indeed a case
offaulty differentiation, or, as I phrase it, "Oncogeny is blocked or partially blocked
Ontogeny" [3]. In contrast to the usual inference, however, I prefer the hypothesis
that the faulty differentiation results from alterations in DNA structure, i.e., either
somatic mutations in the usual sense, or by viral modifications of the genome,
operationally equivalent to mutations.
Thus the three majortheories to explain cancerwould all be integrated into a single
framework in which faulty differentiation is coupled with either one of the two
others. This concept can be further elaborated in terms of failures in the normal
intercellular communication that involves positive and negative feedback between
differentiated cells acting on their less differentiated precursor or stem cells, as I will
indicate.
The idea of faulty differentiation leading to breakdown in intercellular communi-
cation is presently being illuminated by basic science advances in the understanding
of the phenomena of initiation and promotion, which I shall report today. My major
conclusion will be that promoters cause activation of genes for growth factors in
normal and initiated cells by derepression. This derepression is brought about by
blocking the formation, transmission, or reception of repressors (i.e., inhibitors or
chalones [4]). Repressors normally act between differentiated cells and cells that
are capable of dividing, in order to control proliferation.
I will begin by discussing the concepts of initiation and promotion, which have by
now received acceptance by many cancer investigators [5].
Promoters are not carcinogens. At the outset it is important to make clear what we
mean by the words promoter, initiator, and carcinogen. In order to be effective as a
carcinogen in the usual type of laboratory test, a compound almost certainly acts
both as an initiator and as a promoter. On the other hand, at very small ("subcarci-
nogenic") doses, the so-called "complete" carcinogens can act more like "pure
initiators," and will not produce tumors when the usual numbers of animals are
employed. Thus in the absence of promotion the dose-response at low levels of a
carcinogen should exhibit a threshold effect, because the dose may be too low to elicit
promotion and therefore too low to produce cancers. In contrast, when higher doses
are applied continuously in diets or inskin painting procedures, promotion as well as
initiation occurs and cancers result. My own recent work, as yet unpublished, has
dealt with the induction of liver tumors in rats with low doses ofa known carcinogen
in the presence and absence of a known promoter.
Initiators, or the initiating aspects of complete carcinogens, cause alterations in
DNA structure and are mutagenic by virtue oftheir reactivity as electrophiles or after
being metabolized to an electrophilic form, according to the well-known work of
James and Elizabeth Miller [6]. Sporn and Newton have recently commented that
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"classical strong'carcinogens'. . . all of which are known to damage DNA and to be
highly mutagenic, may be postulated to have the ability to inactivate the genes that
normally repress the synthesis oftransforming proteins, and thus to activate synthesis
of transforming proteins in an irreversible manner" [7]. In other words, they would
regard transformation as a derepression that results from a mutation.
Promoters do not damage DNA and are not mutagenic. However, they do affect
phenotypic gene expression and favor cell proliferation so long as they are present
[8]. Promoters have been shown to affect cell differentiation [9] and to block
intercellular communication [10,11,12], of which more will be said later. It is
proposed here that promoter action includes the derepression of initiated cells by
virtue of the action of the promoter on normal cells, which may decrease the output
of chalones or increase the output of growth factors.
The concepts of initiation and promotion are validated in the final analysis by the
fact that the phenomena of "pure initiation" and "pure promotion" have been
documented (see below). It seems undesirable to call promoters carcinogens and then
use the label as evidence [12] that there are exceptions to the expanding generaliza-
tion [6] that carcinogens are electrophiles and damage DNA.
Thus neither initiators nor promoters are carcinogens. Acting alone they do not
produce cancer, or we may say produce cancer at a very low probability. In contrast,
while acting together in proper sequence, they can produce cancer in nearly 100
percent of animals, using relatively small experimental groups, e.g., 20 to 30 animals.
We thus pose a problem for basic science and a hypothesis upon which to proceed.
Problem: How to explain extremely low cancer probability by initiators or
promoters acting alone and high probability when acting in appropriate
sequence?
Hypothesis (in simplest form): Cancer results from two or more relevant
mutations: Promoters enhance proliferation of cells with one relevant muta-
tion; this increases the probability of obtaining one cell with two relevant
mutations.
The development of this hypothesis will be the purpose of this lecture. Relevant
literature on the two-hit or multiple-hit mutation theory of cancer is available
[1,13-16]. Bell [17] has commented "it is possible that the action of the 'promoter' is
simply to expand the mutant clone to a critical size." My hypothesis combines these
ideas.
Modelsfor Demonstrating Initiation and Promotion
The experiments that have defined the concept of initiation and promotion were
begun by Berenblum, who studied the production of skin tumors in mice [18].
However, the methodology has been extensively refined and extended by R.K.
Boutwell of the McArdle Laboratory, who has gone on to explain tumor promotion
as gene activation [19]. Figure 1 is taken from a recent report by Boutwell [20] since it
describes the classic example of initiation and promotion. It will be noted that no
tumors in mouse skin result when only initiator is applied, or only the promoter, or
when the sequence is reversed or when promoter is not applied at an appropriate
frequency. However, when a singleapplication ofinitiatorisfollowed byapplications
of promoter at suitable frequency many skin tumors result. In these experiments the
number of mice with tumors is nearly 100 percent when both initiation and
promotion occurred. This type of experiment raises several issues not immediately
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No Tumors FIG. 1. Initiation and promotion in
mouse skin. From Boutwell [15]. The
No Tumors application of a single subcarcinogenic dose
of a carcinogen such as benzanthracene or
Many Tumors dimethylbenzanthracene can act as an ini-
tiator, while croton oil or 12-0-tetra-
No Tumors decanoylphorbol-13-acetate (TPA) given
repeatedly at suitable intervals can act as
Many Tumors promoters. Protocol No. 5 indicates that
initiator action is irreversible and consider-
6) -j--IA/ ihlAlblAlAlAlAlAlfr* No Tumors anle intervals ot time can intervene between
the application of initiator and promoter.
Protocol No. 6 indicates that if intervals of
Symbols: Time time between promoter applications are too
Initiator Promoter long, no tumors will result. Not shown but
implied by Protocol No. 6 is the fact that
single applications of promoters are ineffective in the case of the classic mouse skin experiments.
apparent. First, it appears that with moderate numbers of animals there can be a
threshold effect with no tumors developing with "subcarcinogenic" single doses of a
carcinogen employed as an initiator not followed by a promoter. Skin tumors are
produced only with larger doses ofthe carcinogen, in which case the carcinogen needs
no second chemical. Second, since application of promoter to skin treated with an
initiator or subcarcinogenic doses of a carcinogen will produce many tumors, it is
evident that skin treated only with initiator must contain many altered cells that
cannot be identified under the microscope. These altered cells are what I will call
"operationally normal" in the absence of promotion. This idea is pertinent to the
experiments used to argue that tumor cells are not mutants [2] since it proves that
mutant cells relevant to cancer can be operationally normal in the appropriate cell
microenvironment.
The point is that in real life many people can be exposed to subcarcinogenic or sub-
threshold levels of a carcinogen and never develop cancer even though they may have
substantial numbers of initiated cells at what I will refer to as Stage I Inhibited, i.e.,
repressed, single mutant cells. This concept is very important to our understanding of
lung cancer in men and women as a result of cigarette smoking. In my opinion lung
cancer in the human is the second classic example of initiation and promotion. This
possibility has been the subject of an editorial in thejournal Lancet [21]. In 1959 Roe,
Salaman, and Cohen [22] carried out experiments demonstrating promoter activity
in cigarette smoke condensates. They concluded, "The correlation between smoking
habits and lung tumour incidence may well be determined not primarily by the
carcinogenic effect of tobacco smoke but by its predominantly tumor promoting
action on the bronchial epithelium." Direct support for this conclusion is available on
the basis of studies on the bronchial epithelium of 216 carefully matched smokers,
former smokers, and non-smokers who had died of causes other than lung cancer
[23]. The "former smokers" had smoked for at least ten years but had not smoked for
at least five years before the time of death. My conclusions are based on thefindings
that 93.2 percent of the 3,156 sections from 72 smokers contained atypical cells while
only 6 percent of 3,436 sections from 72 "former smokers" contained such cells and
only 1.2 percent of the sections from non-smokers showed atypical cells. The study
suggests that discarding the smoking habit may be helpful in preventing lung cancer
no matter how many times it has to be attempted. In discussing the above results,
1)
2)
3)
4)
I
I I I I I I
I I I I I
I I I I I I I I I I I I I I I I
U I
if
370INITIATION AND PROMOTION IN CANCER FORMATION
E. Cuyler Hammond expressed a theory ofcarcinogenesis that is almost a paraphrase
of the initiation-promotion concept [24] as presented in this paper. Hammond
regarded the cells with atypical nuclei to be genetic variants ("I will assume them to
be such" he said [24]). He continued, "I next propose that some of the variant cells
with atypical nuclei are better adapted to anenvironment containing cigarette smoke
products than are ordinary cells." In the smoke environment the bronchial epithelium
can cause both hyperplasia and metaplasia. In the former there is an increase in the
number of basal cells fromjust one or two rows to as many as 20 or more rows with
"little or no changes in the size or appearance ofindividual cells." This is essentially a
description of promotion. Hammond's theory of carcinogenesis is essentially a
concept that cancer involves both somatic mutation (initiation) and a changed
microenvironment that encourages proliferation of initiated cells (promotion).
Hammond interpreted the earlier findings [23] to mean that "If the individual stops
smoking, the [micro]environment reverts to freedom from cigarette smoke products,
the selective process is reversed and ordinary cells replace variant cells" [24]. I agree
with his views and merely add a hypothesis that is self-evident, namely, that the
proliferation of cells with one or more relevant mutations directly increases the
probability of getting a cell with additional relevant mutations, as I will describe
below.
The thirdmodel of what is now widely regarded as initiation and promotion is the
case of liver cancer produced in experiments with rats. Many experiments on liver
carcinogenesis have been carried out at the McArdle Laboratory by the Millers, by
Henry Pitot, by Brian Laishes, and by me as well as by other groups throughout the
world. From among the latter I will present charts adapted from the reports of Roy
Albert et al. [25] at New York University and Carl Peraino et al. [26] at the Argonne
Laboratory (Fig. 2). Albert fed acetylaminofluorene (AAF) at a variety of levels
(0.001, 0.003, 0.01, and 0.03 percent) in the diet for various periods oftime(8, 16, and
32 weeks). In terms ofthethreshold concept, it is interesting to note that even with 32
weeks of treatment and over 80 weeks ofobservation, no tumors were seen at the two
lower levels ofAAF. Tumors were observed after exposure to diets containing0.01 or
0.03 percent AAF but the incidence was greatlydelayed at the lowerdietarylevel, and
in fact no tumors were observed when 0.01 percent AAF was administered for eight
weeks. It is my opinion that in these experiments there were single mutant Stage I
cells present in the livers at the ineffective doses ofAAF. In order to obtain tumors it
was necessary to administer AAF at adequate doses for longer times. This was
sufficient to bring about promotion to what I call Stage II, TheCritical Mass, and to
provide sufficient time to permit progression to the rapidlygrowing large liver tumor.
In terms of the threshold concept, it is not possible to calculate the probability of
cancer production at low doses of AAF by using large doses of AAF for longer
periods because at the low doses promotion is not present and at the high doses
promotion is present. I make this claim because in 1973 Carl Peraino et al. [26]
carried out a crucial experiment, also shown in Fig. 2, in which 0.02 percent AAF was
given for only 18 days and then followed by either basal diet or a diet containing0.05
percent phenobarbital, which most people now believe to act as a promoter of liver
carcinogenesis in these experiments[27]. The data in Fig. 2 show the incidence ofrats
with tumors 1 cm in diameter orlarger in the Peraino experiment. In my laboratory I
havejust completed an experiment with0.015, 0.030, and 0.045 percent AAF for only
14 days, followed by 0.05 percent phenobarbital. The data for this experiment are in
process. I wish to emphasize that the goal of my own experiments is to find the lowest
amount of AAF that will produce demonstrable lesions in liver when followed by a
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FIG. 2. Initiation and promotion in rat liver. Replotted from Albert et al. [25] and Peraino et al.
[26]. In the experiments by Albert et al. no promoter was used and it is here inferred by comparingthe
data with that of Peraino et al. that at the lower levels of 2-acetylaminofluorene (AAF) for the shorter
periods of time the AAF was ineffective as a promoter. In contrast, in the experiments by Peraino et al.
hepatomas were produced by 0.02 percent AAF in the diet for only 18 days when followed by
phenobarbital acting as a promoter [26,27]. Phenobarbital alone produced no hepatomas.
promoter and to inquire whether hepatocarcinomas are produced at these exposures.
There are still no hard data anywhere on liver tumor incidence as afunction ofAAF
dose in the lowest ranges used by Albert et al. (0.001 and 0.003 percent) followed by
maximal promotion. At this time I can state that under conditions as in the Peraino
experiment in Fig. 2, phenobarbital alone does not produce any hepatomas; that is, it
acts as a pure promoter in the case of rat liver carcinogenesis. I will now turn to some
of the background for the modern studies.
Clinical Origins ofthe Promoter Concept
All of the present basic science approaches to chemical carcinogenesis have a
background in the past. There were many indications that led people to believe that
irritation had something to do with cancer. However, there were only a few
observations that seemed to indicate the possibility that irritation per se was not the
cause of cancer but that it mattered only when some earlier event had occurred. I am
aware of only two such cases:
In 1761 John Hill, an English physician, wrote as follows [28]:
Whether or not [cancers], which attend Snuff-takers, are absolutely caused by
that custom: or whether the principles of the disorders were there before and
Snuff only irritated the parts, and hastened the mischief, I shall not pretend to
determine . . .
Over 100 years later, in 1874, Francesco Durante, an Italian physician, summa-
rized a series of his clinical experiences with the following statement, in which he
drew on an analogy that he related to his own clinical experience [29].INITIATION AND PROMOTION IN CANCER FORMATION
Such elements remain enclosed withinwell matured tissuefor years and years,
betraying not the least indication oftheir presence, until an irritation, a simple
stimulus, suffices to rekindle in them movement and cellular activity as is
excited by heat within elements of the germinal macula of fowls' eggs ...
Basic Science Origins ofthe Promoter Concept
In 1974 Boutwell [19] in reviewing the status of the promoter concept noted that,
following the observations of John Hill in 1761,
Nearly 150 years elapsed before Yamagiwa and Ichikawa in 1915 showed that
similar lesions could be produced experimentally by the repeated application
of coal tar condensate to the ears of rabbits ... By 1918 Tsutsui had shown
that mice were also responsive ... Because the coal tar caused inflammation
and wounding these men concluded "The repetition or continuation of
chronic irritation may cause cancer" in confirmation of Rudolf Virchow's
hypothesis.
Here the point is that when the experimental production of cancer in rabbits and
mice with coal tar was first achieved there was no intuition that separated the idea of
irritation from the idea of cancer production by chemicals. It took a long time forthe
isolation of precisely those chemicals that would produce cancer when applied
repeatedly in sufficient amounts. The definitive story oftheir isolation from two tons
of coal tar in the 1930s cannot be detailed here but the exact structures were worked
out and they could be chemically synthesized. Among them was the aromatic
hydrocarbon, 3:4 benzpyrene, which was widely used for the production of skin
cancer in mice. Anauthoritative account ofthework by Sir Ernest Kennaway and his
collaborators has been published [30] and reference works are available [31]. With
pure carcinogenic compounds available investigators could now do experiments that
would separate the idea of irritation from the idea of carcinogenesis. The first hint
came from the pen of Berenblum in 1941 while still in England even before he had
carried out experiments that clearly separated promotion from initiation. He began
to suspect that irritation was not inevitably carcinogenic and wrote as follows [18]:
In clinical discussion on the relation of irritation to carcinogenesis, there is a
tendency to oversimplify the issue by considering only 2 possibilities, either
that all irritants are carcinogenic, orthat irritation has nothingwhateverto do
with carcinogenesis.
In the same paper, he reported experiments with a known irritant, croton resin or
croton oil, obtained from the croton bean. Although it was some years before the
more elegant experiments were carried out [19,20], Berenblum stated the problem
quite clearly:
Was it possible that among [irritants] there were some which, without being
themselves carcinogenic, could augment the tumor-producing action of a
carcinogenic agent when the degree ofirritation by the latter was insufficient?
Berenblum used the word cocarcinogen and originally used a carcinogen and croton
oil together. Meanwhile other experimenters used drastic methods to induce wound
healing in areas pretreated with a carcinogen. Thus Peyton Rous and coworkers used
cork borers to punch holes in pretreated rabbit ears and observed increased cancer
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formation on the healing margins. They wrote the first paper with the words
initiation and promotion in the title [32] and commented as follows:
Many of the hidden entities, which ordinarily would not come to anything as
the late findings show, can be induced to assert themselves and form visible
tumors by agents or conditions which do not themselves initiate neoplastic
change...
Origins ofthe Modern Era
At almost the same time, in 1944, an English investigator J.C. Mottram [33]
performed a key experiment that set the stage for many more elegant experiments by
Boutwell and others [19,20]. His report included the idea, not fully exploited, that a
single application of a subcarcinogenic dose of a carcinogen could be employed to
study the effect of a promoter. He wrote as follows:
The combination ofcroton oil with benzpyrene provides a much more delicate
test than the sledge-hammer treatment of continuous painting . .. By its use
very short paintings with benzpyrene-even a single painting-sufficed to
produce both benign and malignant epidermal tumors.
From these early beginnings in 1941 and 1944 it required nine more years for another
milestone when it was shown by Salaman and Roe [34] in England that ethyl
carbamate (urethane), a very simple compound, can act as a pure initiator of skin
cancer in mice.
The object of the present work was to test the hypothesis that there exist also
initiating agents which are not carcinogens, at any rate for the tissue under
treatment.... It is concluded that urethane is an initiator of carcinogenesis,
but not a carcinogen or a co-carcinogen, for mouse skin.
They showed that urethane alone produced no skin tumors. However, when
followed by croton oil in multiple treatments many skin tumors resulted.
Their report was almost immediately repeated and confirmed by Berenblum and
Haran who reported two years later [35]:
These results support the findings of Salaman and Roe (1953) that urethane,
itself non-carcinogenic for mouse skin, can induce the initiating phase of
carcinogenesis in that tissue.
These two reports are extremely significant because they show that promotion can be
the decidng factor for cancer production. If a completely non-carcinogenic com-
pound can be capable of producing cancer when followed by a promoter, what about
the many compounds that seem to be weak carcinogens because, like urethane, they
exert little or no promoting activity? What about the situation in which humans are
exposed to small doses of strong carcinogens followed by conditions that are not
promoting? The data are also vital to the concept that initiated cells can be
"operationally normal."
The point is that a Stage I initiated cell can behave as a normal cell in one
microenvironment and as a neoplasm in another, just as John Hill and Francesco
Durante suspected over 100 years ago. There are many references in the literature to
the concept of the "sleeping" or "dormant" tumor cell [36]. Experiments with
initiators and promoters now provide the opportunity to learn how hormone
imbalances and life styles may relate to cancer. An example of contrasting life styles
is seen in the case of heavy smokers vs. occasional smokers.
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Feedback Control by Differentiated Cells
For some time there has been in theliterature afundamental idea that is the parent
of much current research. I have elsewhere [3] referred to it as the Osgood Principle
and cited Osgood's efforts at the University ofOregon dating back to 1950[37,38]. In
1957 he stated the principle that "with the majority of cell series the homeostatic
regulator is an inhibitor of arithmetic cell division and is probably produced by the
most chemically mature of the differentiating cells of that series" [37]. The same idea
was put forth at about the same time by Weiss and Kavanau [39] and has been
extensively discussed by Iversen[40]. I suggest that there are two models forfeedback
control of cell proliferation. In the first model (Fig. 3) the organism sends signals
TWO MODELS FOR REGULATION OF
PROGENITOR CELL REPUCATION
MODEL L'ORGANISM REGULATES PROGENITOR DIRECTLY
XS SYSTEMIC SIGNALS - ORGANISM
Gp GI
L.M . A. G .GNth CL GL M\ L GoA------Go TERMINALLY CELL
PROGENITOR DIFFERENTIATED DEATH
CELL CELL (GT)
ORGANISM-
SERVING
MOLECULES
MODEL H: ORGANISM COMMANDS
PROGENY TO REGULATE PROGENITOR
ORGANISM
PROGENITOR RECEpSYSTEMIC SIGNALS PROGENITOR ~RECEPTRS -
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r -4s-* _CSFODIFFERENTIATED DEATH
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FIG. 3. Two models for the regulation of progenitor cell proliferation. Modified
from Potter[3]. Both models illustrate the role of the progeny cells in regulating
the proliferation of stem cells. Model I illustrates the general case, while Model 11 is
more in line with the proposals by Osgood [37,38], Weiss and Kavanau [39] and
Iversen [40], all of whom emphasized negative feedback. The inclusion of positive
feedback in the scheme [3] is based on the recent work of Kurland et al. [41]. In
both models, the cell cycle is shown in the conventional waywith M for Mitosis, S for
DNA synthetic period, GI for the time gap before S, and G2 forthe time gap between
S and M. G0 toG0th represents a series ofstages in differentiation that are still able
to get back to G, and move into the cell cycle. The superscripts A to Nth represent
special cell properties that characterize a particular stage and may be transiently
expressed. GT(from ref. [3]) represents a stage ofterminal differentiation beyond Go
and no longer able to return to GI. "Organism-serving molecules" such as hemo-
globin form the link between the terminally differentiated cells and the organism,
and the term is preferred to "luxury molecules" [3].
In Model 11 CSF is for ColonyStimulating Factor, which is a glycoprotein [41].
There appear to be a number of glycoproteins with this function and with different
sources and target stem cells. The balance between G, and Go is not fixed but can
vary according to the balance between positive and negative feedback factors. The
prostaglandin PGE shown in Model 11 is based on a particular cell system [41] and
the negative feedback indicated for PGE is not to be generalized, since many other
substances perform the chalone function depending on the tissue [40].VAN RENSSELAER POTTER
from differentiated cells of a different series, e.g., kidney, to the stem cells of a line
that gives rise to quite different cells, e.g., in bone marrow. However, this is but a
modification of the Osgood Principle, which is shown as model II in Fig. 3. Here it is
emphasized that both growth stimulators and growth inhibitors can spring from the
more differentiated cells and can act on the progenitor or stem cells, as demonstrated
by Kurland et al. in 1978 [41]. These feedback systems are actually the means of
control by which normal cells can repress gene expression in initiated cells or in each
other. It is this feedback control by normal differentiated cells that I am proposing as
the significant locus of promoter action. Feedback may conceivably act either to
control gene availability or phenotypic expression of available genes.
That control of gene expression is a many-splendored thing is illustrated by Fig. 4.
In this figure it may be noted that at least six categories of regulatory sites of action
may be specified. Many more could be documented. In examining differentiation at
the molecular level it should be recalled that in any given cell only a small fraction of
the total genome is available for transcription. Availability of a DNA sequence does
not imply that transcription is occurring at the same rate at all times. Thus
modulation of phenotypic expression can occur at four levels:
1. Change in enzyme activity without enzyme synthesis
2. Change in enzyme amount (by synthesis or degradation)
3. Change in enzyme amount with mRNA synthesis from available genes
4. Change in mRNA amount with change in DNA availability
A SEQUENCE OF MOLECULAR RESPONSES FOR
PHYSIOLOGICAL ADAPTATION TO STRESS OR CHANGE
Q) CELL
DNA --REPLICATION
PHENOTYPIC ,2 FEEDBACK
EXPRESSION CIRCUITRY
mnRNA
tRNA AND rRNAz, INFORMATION
PRODUCT -'
INACTIVE ACTIVE METABOLIC
PROTEIN PROTEIN PATHWAYS
ORGANISMIC SIGNALS SUBSTRATE SUBSTRATES-I
10 I tATP
INACTIVE ACTIVE NUTRIENT ORGANISM-
PROTEIN PROTEIN '2-'TRANSPORT SERVING
KINASE KINASE MOLECULES
CYCLIC AMP - ATP
-
ADENYL CYCLASE
AMP ORGANISMIC SIGNALS
FIG. 4. Six categories for the modulation of phenotypic gene expression. The regula-
tion of cells in Go and GT stages in Fig. 3 may be seen as physiological adaptations to
environmental stress or change. The numbers in the chart indicate to some extent the sequence
of responses by cells in the Go stage, while cells in GT no longer have the sixth response open
to them. The scheme includes the action ofcyclic AMP via protein kinases that phosphorylate
proteins, making them either active or inactive, and it is also indicated that not all protein
kinases are cyclic AMP dependent.
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It seems likely that in various examples of differentiation the fourth category is
involved, while maturation in a cell series may involve only the third category.
The Stages of Chemical Carcinogenesis in Liver
As a result of current studies in my own laboratory and of work with which I am
acquainted I propose a somewhat new scheme of staging categories based on the
concepts of initiation and promotion (Fig. 5). According to this scheme we propose
five stages that are relevant either to continuous carcinogen treatment or to
initiation-promotion treatments:
Stage I-Inhibited single mutant cells
Stage 11-Critical mass of cells
Stage III-Slow growth subject to fluctuations in host repressors
Stage IV-First appearance of double mutant cell
Stage V-Fast autonomous growth and further mutation in double mutant clones
The individual stages can now be discussed in more detail.
Stages I andII
The methodology employed is a histochemical stain for demonstrating enzyme
action in a thin slice of properly fixed tissue. The method reveals the presence of
gamma-glutamyl-transpeptidase (GGT) by the production of a red dye [42]. A slice of
normal liver appears almost colorless to the unassisted eye, while microscopic
inspection reveals GGT in bile duct epithelium. Our scheme proposes that in Stage I
there are numbers of single mutant initiated cells depending on the dose of initiator
and the number of susceptible cells. However, these single cells are repressed and held
in a non-proliferative state by feedback from adjacent normal cells and possibly by
more distant cells. They are virtually impossible to count at the single-cell stage for
two reasons: they are difficult to see and identify with certainty, and the probability
of hitting any given single cell with only a few slices per liver is very small. The stain
for GGT activity is a method for visualizing cells or clones referred to as "enzyme-
altered foci" always with reference to GGT or whatever other property that can be
visualized histochemically. At this date it is still not clear what alterations are
necessary for a cell to be quiescent in the absence of a promoter and to proliferate in
the presence of a promoter, and the enumeration of GGT-positive foci is taken only
as a measure of the ability of a foreign compound to initiate changes that result in
proliferation when a promoter is administered.
The reason for postulating the existence of Stage I single mutant repressed non-
proliferating cells is based on two lines of collateral research, in addition to the actual
observations of the GGT-positive groups of cells seen when phenobarbital is given.
First, there is a large and growing literature on the existence of tissue-specific growth
suppressors under the name of chalones, for which reports and reviews are available
[4,40,43-46]. But more to the point is a new development that deserves considerable
attention and further research. In the last week of November 1979 two publications
appeared simultaneously, reporting that tumor promoters blocked intercellular
communication, thereby strongly supporting the proposition illustrated in Fig. 5.
One report was from James Trosko and coworkers at Michigan State University[10]
and the other was from Murray and Fitzgerald [11] at the University of South
Australia, using different cell types and different measurements, but with both groups
emphasizing the property of tumor promoters to block intercellular communication.
A third report confirming the phenomenon in liver cell monolayers has been made
[12].
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FIG. 5. Five stages ofdevelopment in the production ofhepatocellular carcinomas
by compounds acting as initiators and as promoters. Experiments with rat liver
have employed acetylaminofluorene (AAF) at low levels for brief periods as an
initiator [26,27] and phenobarbital as a promoter [26,27]. Enzyme-altered foci have
been visualized by a histochemical procedure that reveals gamma-glutamyl trans-
peptidase (GGT) [42]. In the above scheme, open circles represent single cells or
enzyme-altered foci that are subject to chalone action (negative feedback) from
neighboring normal cells, indicated by arrows targeted on the open circles. To
represent the application of the GGT technique, these open circles might be colored
red. The filled circles represent double-mutant or N + I mutant cells that are not
subject to host controls. The double bars through the arrows represent promoter
action blocking the intercellular communication between normal cells and initiated
cells. The double bars between arrows and cells represent a stage at which the
proliferation of cells in the enzyme-altered foci can proceed even in the absence of
promoter, i.e., when the altered cells have reached the stage of "critical mass." The
Stage III cells are in the form of neoplastic nodules that are highly differentiated and
slowly growing, as in the case of the comparable Morris hepatomas [3]. The
"progression through time" is assumed to involve a second or N + I mutation to yield
the cells represented byfilled circles in the chart. This"progression through time" is
postulated to occur without the continued presence of a carcinogen or simple
initiator and to be the result of single (relevant) mutations that occur spontaneously
or as the result of unknown environmental influences. Such single mutations would
not result in a neoplasm except when superimposed upon a genome that has already
had a relevant mutation. The key to the entire scheme is the idea that a second or
N + I mutation with a low probability becomes increasingly probable as the popu-
lation of first-stage altered cells increases. "Conversion" represents the experimental
production of a second step in the initiation process acting on one or more cells in the
expanded population of Stage I cells (refer to Table 1).
The only way the number of initiated "single-mutant" cells can be estimated is by
treating the animal with a promoter or a promoting influence that in my proposal
blocks the repression exerted by the normal liver cells. In this situation a clone of
from 1,000 to 10,000 cells will develop and form a mass that is readily seen under the
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microscope. In the case of the larger clones they can be seen on a microscope slide
with the unassisted eye. The probability of hitting a clone with a single liver slice
depends in a complex way on the size of the clone. Formulae for taking the
probabilities into consideration have been worked out and applied by Scherer et al. in
Amsterdam [47]. Other methods are being investigated by Dr. H.A. Campbell in
connection with experiments referred to earlier (unpublished). After sufficient time
has passed many of the clones will have attained a sufficient mass to be able to
survive and grow slowly in the absence of the promoter even though subject to
fluctuations in host repression. This is Stage II, the critical mass.
The newer techniques for visualizing clones of enzyme-altered cells are very
dramatic and there are now at least four different properties that have been visualized
[48-51]. It has been a thrilling experience to look at a liver section and to see masses
ofaltered cells for the first time, using the GGT technique even though subsequent
experience has shown that these cells are not necessarily destined to become cancer
cells. Work in my laboratory has suggested to me that there may be single mutant
cells and clones that cannot be visualized by any of the available techniques, and in
fact there can be hepatomas that do not stain for GGT [52].
Stage III: Slow Autonomous Growth
Just as the number of initiated cells can be appreciated only by promoting their
proliferation and allowing time for them to reach a feasible size, the number of cells
that have attained critical mass can be appreciated only by withdrawing the promoter
and allowing sufficient time for the regression of the clones that have not attained
critical mass. It is possible or even likely that the various clones at this stage include a
variety of combinations of mutations and that the designation "single mutant" is an
over-simplification, since thpre must be many kinds of single mutant cells and cells
containing two or more mutants. Various combinations ofenzyme alterations within
single livers have been demonstrated by Pitot et al. [48] and by Goldfarb and Pugh
[49]. That the phenomenon of regression to what I would call "operationally normal"
cells when carcinogen or promoter is withdrawn was suggested by the earlier work of
Teebor and Becker [53] and more recently by the work of Gary Williams and
coworkers [51,54] whose tabulated data I have converted to graphic form.
In Fig. 6 are shown the data for the rate of appearance of different sizes of altered
enzyme foci as a function of time on a diet containing 0.02 percent AAF, expressed as
foci transections per sq cm not corrected for probability of hits (left panel). In the
right panel are shown similar data for the disappearance of the altered foci when the
animals were placed on a basal diet. It may be seen that nearly all the foci
disappeared.
In Fig. 7 further tabulated data from Hirota and Williams [54] are shown
graphically. My purpose is to illustrate the change in the numbers of StageI, StageII,
StageIII, and Stage V cells with time. With continued exposure to a diet containing
0.02 percent AAF the numbers of enzyme-altered foci transections increased. When
the AAF diet was discontinued the numbers dropped sharply by 12 weeks, but the
numbers increased somewhat by 24 weeks as critical masses of cells continued to
expand and become more likely to be counted. But it is emphasized that the number
of altered foci would calculate to thousands per liver as reported by Pitot [56], while
the number of Stage VI nodules was in the range of 0 to 20 per liver and the number
of cancers after 48 weeks off the diet was in the range of 0 to 3 per liver. My
interpretation of these findings is in terms of Stages Ito III for the assumption ofthe
379VAN RENSSELAER POTTER
E 13 WEEKS ON AAF 13 WEEKS ON AAF
U CO.02%) +4 WEEKS OFF
O 120
0
w 80-
uJ w~~~~~
12 WKS 1~~~2
(WKS\
40 D OFF
24 \
4' I WKS)I
\ WKS OFF
0'~ I
0 10 20 3(0 40 0- 10 20 30 40
DIAMETER OF ENZYME-ALTERED FOCI Cd) (NO. OF CELLS)
0 524 4200 14000 33500 0 524 4200 14000 33500
r3 x 4.189=CELLS PER SPHERICAL MASS
FIG. 6. Appearance (left panel) and disappearance (right panel) of enzyme-altered foci in
livers ofrats fed diets containingacetylaminofluorene (AAF) or basal diet for various periods of
time. The charts were made by plotting data from tables published by Williams and
Watanabe [51] (with permission ofG.M. Williams). In every case the wordfocishould readfoci
transections since the foci were seen in transection in a 2-dimensional liver section and reported
per cm2. The charts show the distribution of focus transections as a function of their diameter
expressed as number of cells. The number of cells per spherical mass is a calculation (not in the
original report) which would require that the diameters are based on transections through the
center of aspherical mass, which cannot be assumed. The number offoci per cm3 is not a simple
function of foci transections per cm2 because of the decreased probability of hitting a focus as
the size becomes smaller [47].
need for a further mutation (Stage IV) to account for the much smaller number of
cancers in Stage V at the end of the experiment.
Stage IV: The Occurrence ofa Second or (N + 1) Mutation
It is well known from our previous work that there are highly differentiated
hepatomas that grow veryslowly and respond to glucagon by producingcyclicAMP,
while other, more rapidly growing hepatomas do not respond to glucagon [57]. We
propose that the rapidly growing hepatomas have at least one additional mutation
and that the numbers shown in Fig. 7 derive from this possibility. Promotion would
enhance the possibility of a second mutation because ofthe increased number ofcells
with one mutation. In contrast to this route, the probability of a second mutation
without promotion is very small because there are vastly fewer cells available for a hit
(Fig. 5).
Thus, the overall scheme (Fig. 5) shows twopathways to the Stage V progressed
tumor, or hepatocellular carcinoma in this system. I refer to the low probability
pathway in the absence of promotion and the higherprobability by a factor of 1,000
or more in the presence ofpromotion (Table 1). In the case of urethane-treated
mouse skin, as I mentioned earlier, there were no tumors in the absence ofpromoter
and high incidence in its presence [34,35]. Relevant to this figure I emphasize the
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FIG. 7. Enzyme-altered foci transections per cm2, neoplastic nodules per liver, and hepatocellular
carcinomas per liver as a function of time on or off a diet containing 0.02 percent acetylaminofluorene
(AAF). The charts were made by plotting data from Hirota and Williams [49] (with permission from
G.M. Williams). The ordinate expresses the number of foci transections per cm2 as noted in Fig. 6.
"Cycles" refers to periods of AAF feeding followed by a period of basal diets as indicated on the abscissa.
Groups of animals reveived AAF for three cycles ( * or o ), four cycles ( * or o ), or five cycles ( A orA ).
Solid lines represent the time during cycling. Dashed lines represent the time when animals were
permanently shifted to basal diet. None of the groups in this chart or Fig. 6 received phenobarbital. In a
separate publication Williams and Watanabe [55] reported that when phenobarbital was given in place of
basal diet following AAF, the marked decline in foci transections seen in Fig. 6 and Fig. 7 did not occur.
experimental fact, never demonstrable before the studies on enzyme-altered foci, that
there are thousands of enzyme-altered foci at Stage I even with low doses of AAF,
when visualized with the aid of a promoter. Later there are only a few dozen
promotion-independent foci as Stage III, and finally there are either no or only a few
rapidly growing hepatocelluar carcinomas at Stage V. These numbers are very rough
and much further work will be required to improve their accuracy and significance.
However, I have used the order of magnitude of these numbers, plus the recent
findings of Trosko and others [10,11,12] to suggest that promoters act to block the
repression of initiated cells by normal cells, thereby leading to their proliferation.
Depending on the degree of proliferation of the first stage cells, the probability of
further stages is greatly enhanced. Together the available data appear to support the
hypothesis I proposed in the beginning. This hypothesis is based on the vast literature
now available regarding the mutational nature of initiation and the non-mutational
nature of promotion [58,59]. Moreover, the phenomenon appears to be applicable to
a variety of tumors [56]. Wider appreciation and understanding ofthe phenomena of
initiation and promotion is important because the available data suggest that (1)
there may be a low risk of human cancer at levels of carcinogens too low to elicit
promotion, and (2) more effort should be made to evaluate the identification and the
role of promoting influences in the overall risk of human cancer. Although the
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TABLE I
Estimation of Effect of Promotion on Probabilities in Chemical Carcinogenesis in Liver*
1. Calculate hepatomasper rat with 2 single low doses ofinitiator separatedin time, with no intervening
promotion.
Hepatomas per rat = Probability of Ist hit x Probability of 2nd hit
No. of cells per liver
Probability of 1st hit = No. of clones after Ist hit plus promotion**
No. of cells per liver
Assume 109 cells/liver.
Assume number of single hit cells = number of clones after single low dose plus promotion of single
one-hit cells to clones**; take 1,000 such clones as an example (= low value)
then, Probability of 1st hit = 1_000 = 10-6
109
Assume Probability of 2nd hit = Probability 1st hit
Assume 2 hits in one cell = Hepatoma
then, Probability of 2 hits per liver = 10_6 X 10-6 = 10-3 per liver
109
= 1 hepatoma per 1,000 rats
2. Calculate hepatomas per rat with 2 single low doses ofinitiation withpromotion intervening to give
clones ofaverage size 1,000 cells.
Assume same no. of 1-hit cells after 1st single dose of initiator = 1,000 cells
Calculate number of 1-hit cells after promotion = number of clones x number of cells per clone
[f(time)]
Assume 1,000 cells per clone (= low value)
then, No. of 1-hit cells after promotion = 1000 x 1000 = 106
then number of cells with 2 hits = No. of hepatomas expected
10-6 (probability per cell) x 106 (no. of cells with I hit)
109 (cells per liver)
1 hepatoma per rat, when promotion intervenes between single low doses of initiator, compared to
1 hepatoma per 1,000 rats with no promotion.
*Based on the assumption that two relevant hits are required to give a neoplasm not requiring
promotion. (Example calculated on basis of 1,000 single-hit cells after single low dose of initiator, and
1,000 cells per clone after promotion. Both are low values.)
**Promotion is needed to permit the counting of the single-hit cells, but is not employed in a group of
comparable rats that receive "2 single low doses of initiation separated in time, with no intervening
promotion."
simplistic form of my hypothesis and of my staging categories may need modifica-
tion, I am convinced that studies on the molecular mechanisms and practical aspects
of initiation and promotion deserve and will get much further attention in the
"Decade Ahead."
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